25 results about "Tumour volume" patented technology

The application relates to the technical field of biological medicine, and discloses a micropeptide miPEP060 coded by a LINC00060 gene and application thereof; the application provides the following application of LINC00060 and the micropeptide miPEP060 coded thereby: preparing a product for predicting tumor chemotherapy efficacy, preparing a product for predicting tumor prognosis; preparing a tumor treatment product, preparing a product for enhancing tumor chemotherapy efficacy, preparing a product for overcoming tumor chemotherapy drug resistance, preparing a product for inhibiting PARP1 enzyme activity or PARylation modification, and preparing a product for inhibiting replication stress response and replication fork stability; the LINC00060 and the micropeptide miPEP060 coded thereby provided by the application can significantly enhance the chemotherapy killing effect of tumor cells or tumor tissues and reduce tumor volume.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

The present disclosure relates to representation learning for treatment response prediction of risk organs and total tumor volume. For predicting the response of radiation therapy, radiomics is used for unsupervised machine training of an encoder-decoder network to predict based on input of image data, such as computed tomography image data, and from segmentation. Then, the trained encoder is used to generate latent representations to be used as input to different classifiers or regressors for predicting the treatment response, such as one classifier for predicting the response for a risk organ and another classifier for predicting another type of response for a risk organ or predicting the response for a tumor.

The invention discloses a closed tumor-free drainage apparatus for abdominal tumors, which relates to the field of medical instruments, and comprises a protective sleeve, a sealing mechanism, a limiting mechanism and a sealing mechanism, the protective sleeve is used for protecting when drainage mass cyst fluid is used for reducing the volume of the tumors aiming at the huge tumors (cystic solid / cystic) of the pelvic and abdominal cavities, and the sealing mechanism is used for sealing and attaching the protective sleeve and the tumor cyst wall. The limiting device is arranged at the top of the protective sleeve and used for limiting and controlling the size of an opening in the top of the protective sleeve and sealing the whole protective sleeve after drainage operation is finished to prevent cystic fluid from flowing out to the pelvic cavity; by means of the protective sleeve, a drainage tube can penetrate through the interior of the protective sleeve to drain cyst fluid in the wrapping block in a clinical operation of excising a huge tumor of the pelvic cavity, the protective sleeve can protect drainage of the drainage tube and prevent the cyst fluid from flowing into the pelvic cavity and generating a spreading risk, and after the cyst fluid of the wrapping block is drained, the size of the wrapping block can be reduced, and the size of the wrapping block is reduced. In this way, excision operation can be conveniently conducted on the masses, and the length of an abdominal incision can be shortened during laparotomy.

The invention relates to the field of tumor volume detection, and discloses a TOF technology-based tumor volume detection device for a gastrointestinal endoscope, the TOF technology-based tumor volume detection device comprises a gastrointestinal endoscope body, a detection head is mounted on one side of the gastrointestinal endoscope body, and a CCD cable, a forceps tube, an air supply tube and a water supply tube are sequentially mounted in the detection head; illumination light sources are symmetrically mounted in the middle of the detection head, a mounting block is fixedly connected to one side of the detection head, an adjusting and limiting structure is fixedly mounted on one side of the mounting block, and a scraping plate is arranged on one side of the adjusting and limiting structure. The scraping plate can be driven by the adjusting limiting structure to clean one side of the detection head, the cleaning efficiency is enhanced through the water spraying structure when the scraping plate is cleaned, the position of the TOF sensor on the mounting block can be adjusted according to requirements by utilizing the adjusting limiting structure, the size of a tumor block is measured by utilizing the TOF sensor, and the detection efficiency is improved. And real volume data of the tumor in the body is obtained.

The present application provides a prognostic marker for neoadjuvant immunotherapy and chemotherapy of lung cancer, which is the change rate of tumor volume before and after early treatment of lung cancer. In the early treatment of lung cancer, by combining the method of artificial intelligence, the volume change of tumor lesion is used as the feature of treatment effect, and it is observed from the Kaplan-Meier curve that the change amount of tumor volume has a more obvious difference between the two groups of patients.

The present disclosure provides microbial consortia that are useful as therapeutics, for example, for treating cancer and / or reducing tumor volume or tumor growth in patients.

The present disclosure provides microbial consortia that are useful as therapeutics, for example, for treating cancer and / or reducing tumor volume or tumor growth in patients.

The application discloses a non-small cell lung cancer fractionated radiotherapy progress prediction method based on a mathematical mechanism model, which is based on in-depth research on tumor proliferation mechanism and radiotherapy killing effect, and simultaneously carries out segmented integral analysis on the fractionated radiotherapy process, constructs a mathematical mechanism model considering dynamic growth change of tumor volume in the fractionated radiotherapy process, and realizes non-small cell lung cancer fractionated radiotherapy progress prediction by using the mathematical mechanism model. The application can use low-cost python software to realize one-key personalized simulation of NSCLC fractionated radiotherapy progress, provides a new visual angle of numerical simulation for doctors, accurately predicts the volume change of the tumor of a patient after fractionated radiotherapy, and provides a recommended scheme, potential opportunity, reference dose and interval frequency and the like for intervention and intervention of radiotherapy planning.

The invention discloses a GPC3 targeting chimeric antigen receptor gamma delta T cell and an application thereof in treatment of hepatocellular carcinoma. The CAR-gamma delta T cell has a third-generation CAR structure and has high targeting accuracy and killing efficiency, the in-vitro killing rate of GPC3 positive hepatoma carcinoma cells (HepG2 / Hep3B) is larger than 90% (the efficiency-target ratio is 10: 1) and is obviously improved compared with that of common gamma delta T cells, the tumor size is obviously reduced in a PDX mouse model, and the excellent treatment effect of the CAR-gamma delta T cell is proved.

This disclosure relates to modulating IL-2 expression / activity to prevent or treat diseases (cancer, autoimmune diseases, inflammatory diseases, or infections). Compounds of formula (I), as well as compositions comprising their conjugates, complexes, and pharmaceutical compositions, as well as methods of using them to modulate (e.g., increase) IL-2 expression / activity to achieve desired results (e.g., reduction in cancer cell viability, growth, proliferation, or metastasis; reduction in tumor volume; increase in survival; increase or decrease in immune cell proliferation or activation; increase or decrease in cytokine production; decrease in autoimmunity; decrease in inflammation, etc.). Related pharmaceuticals, kits, and methods of delivering such compositions are described. Compounds of formula (I) and methods for developing or manufacturing their pharmaceutical compositions are provided. Diagnostic and test methods for detecting levels of IL-2 expression / activity, as well as compositions constituting diagnostic or test kits, are further described. JPEG2026513223000025.jpg3642

The utility model discloses a device suitable for measuring the volume of a tumor, and relates to the technical field of medical instruments, in particular to the device suitable for measuring the volume of the tumor, which comprises a measuring cylinder and a placing cylinder, and a communicating pipe is fixedly connected on the side wall of the middle part of the measuring cylinder; when the volume of an in-vitro tumor is measured, clear water is poured into a placing barrel, the water submerges a clamping part, the liquid level in the placing barrel is flush with an upper end opening of a communicating pipe, a circular plate is pushed by an air cylinder to ascend and move out of the liquid level, the tumor is placed on the circular plate, the air cylinder descends and drives all limiting assemblies to clamp the tumor, and the clamping part drives the tumor to be submerged in the water; the volume of the clamping part in the water is not changed, after the tumor is submerged in the water, the liquid level in the placing cylinder is raised, and discharged water caused by the fact that the tumor is submerged in the water flows into the measuring cylinder through the communicating pipe, so that the volume of the tumor is obtained by measuring the volume of the discharged water, and the volume of the tumor is accurately measured.

The application provides application of VPS53 in intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, and belongs to the technical field of biological medicine.The application takes VPS53 as the intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, finds that the copy number of VPS53 gene increases after long-term low-dose irradiation, and the expression level of VPS53 increases.In the thyroid cancer cell line with high expression of VPS53, the expression of VPS53 is knocked down, the proliferation, migration and invasion ability is weakened, the tumor volume is smaller, and the tumor grows more slowly;in the thyroid cancer cell line with low expression of VPS53, the expression of VPS53 is overexpressed, the proliferation, invasion and migration ability is enhanced, the tumor volume is larger, and the tumor grows faster.The application proves that knocking down VPS53 is a candidate intervention target of the occurrence and development of thyroid cancer caused by long-term low-dose ionizing radiation.

A pharmaceutical composition, comprising panobinostat and tazemetostat. Combination of tazemetostat which is an EZH2 inhibitor with panobinostat, pembrolizumab and ipilimumab is clinically used for treating patients suffering from later-stage diffuse midline glioma, H3K27-altered, accompanied with leptomeningeal / pia mater spinalis spread, and patients suffering from primary, relapsing and progressing diffuse midline glioma, H3K27-altered. The pharmaceutical composition has remarkable curative effects, can obviously inhibit tumor growth, reduce the tumor volume, improve the life quality for patients, and prolong the survival time of patients.

Compositions, kits, combinatorial treatments, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, along with increasing median survival of a subject with cancer, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising at least one angiotensin-converting enzyme (ACE) inhibitor.

The invention provides application of a KRAS inhibitor combined with glucocorticoid in preparation of a medicine for treating cancers, and belongs to the technical field of biological medicines. The invention provides a combined application of a KRAS inhibitor and glucocorticoid in preparation of a medicine for treating cancers. Compared with the single use of the KRAS inhibitor or prednisolone, the combined use of the KRAS inhibitor and prednisolone can more effectively inhibit the proliferation and survival of KRAS G12C mutated NSCLC cells and slow down the growth of tumor volume. In addition, prednisolone can relieve the acquired drug resistance problem of KRASi by blocking generation of TNF and I-type IFN induced by a KRAS inhibitor, and prednisolone and prednisolone have a synergistic anti-tumor effect. The two can be directly combined for medication, can also be prepared into a combined agent for treating cancers, and has a good clinical transformation prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a CDCA5 inhibitor in preparation of a medicine for treating ovarian cancer. According to the invention, CDCA5 is knocked out from UWB1.289 and snu251 cells, and Olaparib, MHY1485 or 740Y-P is given to the UWB1.289 and snu251 cells. CCK-8, immunofluorescence staining, a transmission electron microscope and western blot are used for detecting cell viability, autophagy, DNA damage and a PI3K / AKT / mTOR pathway. And establishing a BRCA1 mutation ovarian cancer xenotransplantation tumor model. The overall influence of CDCA5 knockout and olaparib is evaluated through tumor volume, weight and biomarkers. Research results show that knock-down CDCA5 is combined with olaparib to inhibit growth of ovarian cancer with BRCA1 mutation, and autophagy and DNA damage are promoted through a PI3K / AKT / mTOR pathway.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field in combination with administration of at least one composition comprising at least one NF-κB inhibitor.

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and / or preventing postoperative tumor recurrence and / or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and / or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

The invention discloses an anti-bladder cancer traditional Chinese medicine compound tablet based on function modularization and a preparation method. Comprising the following components: a body resistance strengthening module: an astragaloside-selenium nano-composite, an ophiopogonin-selenium nano-composite and rehmannia lipidosome; an evil eliminating module: spreading hedyotis herb PLGA nanoparticles and phellodendrine / coix seed oil microemulsion; and the collateral dredging module comprises centipede-salvia miltiorrhiza sustained release microspheres and achyranthes bidentata-lysimachia christinae According to the invention, a three-module design of strengthening body resistance, eliminating evil and dredging collaterals is created for the first time, and the action mechanism of each path is clear. When the drug is combined with a chemotherapeutic drug gemcitabine, the synergistic interaction index reaches 1.31, and the tumor volume reduction rate is increased to 89% from 62% of single drug treatment.

The invention provides an application of 4-bromo-N-(1-methyl-3-(4-methylbenzoyl)-2H-isoindole-2-yl) benzenesulfonamide in preparation of an antitumor drug, and relates to the technical field of biomedicine. The invention provides an excellent potential of 4-bromo-N-(1-methyl-3-(4-methylbenzoyl)-2H-isoindoline-2-yl) benzenesulfonamide (ISO-1 for short) in the aspect of resisting colon cancer, and a cell experiment carried out by a CCK-8 method in the application shows that the ISO-1 has a direct killing effect on colon cancer MC38 cells. In a mouse colon cancer model constructed by MC38 cells, the treatment effect of the ISO-1 is further confirmed. Experimental results show that compared with an untreated Control group, the tumor volume of each group of mice treated by ISO-1 is obviously reduced. The ISO-1 treatment obviously prolongs the lifetime of tumor-bearing mice. The lifetime is one of gold standards for measuring the effectiveness of anti-cancer drugs.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

The invention provides mannose functionalized supramolecular nanoparticles and a preparation method and application thereof, the nanoparticles are formed by supermolecule self-assembly of a water-soluble amphiphilic compound MaCa in a water phase, and the nanoparticles are used for targeted therapy and early diagnosis of triple negative breast cancer (TNBC). A surface mannose unit of the nanoparticle is specifically combined with a TNBC marker alpha-mannosidase 2C1, and a hydrophobic core loaded drug (such as paclitaxel) or an imaging reagent (such as DiR and MRI contrast agents). Experiments show that the enrichment amount of the particles at the tumor part is 9.3 times of that of a control group, the tumor volume disappears after the particles are treated for 7 days, and the particles have no obvious toxicity. The process is simple and convenient, and an innovative solution is provided for TNBC diagnosis and treatment integration.

Compositions, kits, combinatorial treatments, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, along with increasing median survival of a subject with cancer, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising at least one angiotensin-converting enzyme (ACE) inhibitor.